Familial Chylomicronemia Syndrome Market to Observe Impressive Growth During the Forecast Period (2019-2032), Evaluates DelveInsight | Key Companies – Ionis, Akcea, Arrowhead Pharma, Amryt Pharma

Familial Chylomicronemia Syndrome Market to Observe Impressive Growth During the Forecast Period (2019-2032), Evaluates DelveInsight | Key Companies - Ionis, Akcea, Arrowhead Pharma, Amryt Pharma
Delveinsight Business Research LLP
The Familial Chylomicronemia Syndrome market is anticipated to grow in the coming years owing to the improvement in the diagnosis rate, the rise in the number of companies taking an interest in the development of drugs, the ready uptake of premium-price agents like oligonucleotides with better clinical profiles, non-adherence of the patients to the extremely restrictive low-fat diet and patients with significant interference in their daily activities who will seek for medications.

Some of the leading companies in the Familial Chylomicronemia Syndrome therapeutics market include Arrowhead, Akcea Therapeutics, Ionis Pharmaceuticals, Amryt Pharma, and others.

DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Familial Chylomicronemia Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Familial Chylomicronemia Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Familial Chylomicronemia Syndrome Market

Familial Chylomicronemia Syndrome: An Overview

FCS is a rare autosomal recessive metabolic disorder caused by a mutation in lipoprotein lipase. Lipoprotein lipase is a digestive enzyme in the blood that helps the body break down chylomicrons. People with FCS are either unable to make lipoprotein lipase or have a broken form. This leads to elevated triglycerides and chylomicrons in the plasma, which causes an array of symptoms, including serious episodes of acute pancreatitis. It correlates with significant morbidity and distress among the patients.

Familial Chylomicronemia Syndrome Market Key Facts

  • As per DelveInsight’s estimation, among the 7MM countries, the United States had the highest market size of FCS in 2017, which accounts for approximately 30% of the total market, contributing nearly to USD 0.3 million in 2017.

  • As per DelveInsight analysis, the total diagnosed prevalent cases of FCS in the 7MM were found to be approximately 2,989 cases in 2021, which is expected to increase by 2032. Among these, the US had the highest diagnosed prevalence, followed by Japan.

  • According to the estimates based on DelveInsight’s epidemiology model for FCS, in EU4 and the UK, Germany accounted for the highest cases of the diagnosed prevalent FCS, followed by France and the UK.

  • According to estimates based on DelveInsight’s analysis, the US accounted for nearly 22.9% of the total diagnosed prevalent cases of FCS in the 7MM in the year 2021, which is expected to increase further by 2032. 

Familial Chylomicronemia Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Familial Chylomicronemia Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Familial Chylomicronemia Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Familial Chylomicronemia Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Familial Chylomicronemia Syndrome Epidemiology, Segmented by –

  • Total Prevalent Cases of FCS in the 7MM (2019–2032)

  • Age-specific Diagnosed Prevalent Cases of FCS in the 7MM (2019–2032)

  • Total Diagnosed Prevalent Cases of FCS in the 7MM (2019–2032)

  • Severity-specific Diagnosed Prevalent Cases of FCS in the 7MM (2019–2032)

  • Total Treated Cases of FCS in the 7MM  (2019–2032)

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to be launched during the study period. The analysis covers the Familial Chylomicronemia Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Familial Chylomicronemia Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Familial Chylomicronemia Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Familial Chylomicronemia Syndrome Therapeutics Analysis

Several key pharma and biotech companies are developing therapies for Familial Chylomicronemia Syndrome. Currently, Ionis Pharmaceuticals is leading the therapeutics market with its Familial Chylomicronemia Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Familial Chylomicronemia Syndrome (FCS) Therapeutics Market Include: 

  • Ionis Pharmaceuticals

  • Pfizer

  • Arrowhead Pharmaceuticals

  • Lipigon Pharmaceuticals

  • Ionis Pharmaceuticals

  • Akcea Therapeutic

  • Novelion Therapeutics

And Many Others

Familial Chylomicronemia Syndrome Drugs Covered in the Report Include:

  • ARO-APOC3: Arrowhead Pharmaceuticals

  • Lomitapide: Amryt Pharma/Novelion Therapeutics

  • AKCEA-ANGPTL3-LRx: Akcea Therapeutics/Ionis Pharmaceuticals

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Familial Chylomicronemia Syndrome Competitive Intelligence Analysis

4. Familial Chylomicronemia Syndrome Market Overview at a Glance

5. Familial Chylomicronemia Syndrome Disease Background and Overview

6. Familial Chylomicronemia Syndrome Patient Journey

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Familial Chylomicronemia Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Familial Chylomicronemia Syndrome Unmet Needs

10. Key Endpoints of Familial Chylomicronemia Syndrome Treatment

11. Familial Chylomicronemia Syndrome Marketed Products

12. Familial Chylomicronemia Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Familial Chylomicronemia Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Familial Chylomicronemia Syndrome Market Outlook (In US, EU5, and Japan)

16. Familial Chylomicronemia Syndrome Access and Reimbursement Overview

17. KOL Views on the Familial Chylomicronemia Syndrome Market

18. Familial Chylomicronemia Syndrome Market Drivers

19. Familial Chylomicronemia Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: